UNIGE document Scientific Article - Review
previous document  unige:31385  next document
add to browser collection

Use of pneumococcal polysaccharide vaccine in children: what is the evidence?

Borrow, Ray
Heath, Paul T
Published in Current Opinion in Infectious Diseases. 2012, vol. 25, no. 3, p. 292-303
Abstract Pneumococcal glycoconjugate vaccines (PCVs) are now widely used in infant immunization schedules. These vaccines are also recommended for those at increased risk of pneumococcal infection and to provide optimal serotype coverage to those at increased risk of disease. The 23-valent polysaccharide vaccine (PPV23) is often advised from the second birthday to provide broader serotype coverage. The use of pneumococcal polysaccharide vaccines (PPVs) has in recent years become a topic of much debate, especially for use in children.
Keywords AdolescentChildChild, PreschoolGlycoconjugates/immunologyHumansImmunization, Secondary/adverse effectsImmunocompromised HostInfantPneumococcal Infections/prevention & controlPneumococcal Vaccines/administration & dosage/adverse effects/immunologyRecurrenceRisk FactorsVaccines, Conjugate/immunology
PMID: 22517603
Full text
Article (Published version) (534 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Centre de Vaccinologie et d'Immunologie néonatale (177)
(ISO format)
BORROW, Ray, HEATH, Paul T, SIEGRIST, Claire-Anne. Use of pneumococcal polysaccharide vaccine in children: what is the evidence?. In: Current Opinion in Infectious Diseases, 2012, vol. 25, n° 3, p. 292-303. doi: 10.1097/QCO.0b013e3283531b0f https://archive-ouverte.unige.ch/unige:31385

400 hits

0 download


Deposited on : 2013-11-27

Export document
Format :
Citation style :